Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, China.
Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1366-1373. doi: 10.26355/eurrev_201803_14480.
Acute lymphocytic leukemia (ALL) is a multi-factorial blood disease with unknown pathogenesis. Histone H3K4 methylation was significantly reduced in ALL patients, whereas jumonji AT-rich interactive domain 1B (JARID1B) was the specific demethylase of H3K4me. This study explores the expression level of JARID1B in ALL patients and down-regulated JARID1B expression in ALL cells to explore the function of JARID1B in ALL.
JARID1B mRNA expression level in ALL patients was detected by Real-time PCR. The peripheral blood mononuclear cells from healthy volunteers were selected as control. JARID1B shRNA was transfected with MOLT-4 cells and BALL-1 cells. JARID1B protein expression and H3K4me2 and H3K4me3 levels were detected by Western blot assay. Cell proliferation was assessed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. Cell apoptosis and cell cycle were determined by flow cytometry. Bcl-2, Bax, Procaspase 3, and cyclin P21 expressions were evaluated by Western blot assay.
JARID1B mRNA expression in primary bone marrow cells from ALL patients was significantly higher than that of healthy volunteers (p<0.05). The levels of histone H3K4me3 and H3K4me2 were up-regulated after JARID1B shRNA transfection. JARID1B shRNA significantly inhibited the proliferation of MOLT-4 and BALL-1 cells, induced apoptosis, and blocked cell cycle in G0/G1 phase compared with the control group (p<0.05).
JARID1B is highly expressed in ALL. Down-regulating its expression inhibited leukemia cell proliferation, promoted apoptosis, and blocked cell cycle in G0/G1 phase through histone H3K4 methylation. JARID1B is an oncogene in ALL.
急性淋巴细胞白血病(ALL)是一种发病机制不明的多因素血液病。组蛋白 H3K4 甲基化在 ALL 患者中显著降低,而 jumonji AT 丰富的相互作用域 1B(JARID1B)是 H3K4me 的特异性去甲基酶。本研究探讨了 ALL 患者中 JARID1B 的表达水平,并下调 ALL 细胞中的 JARID1B 表达,以探讨 JARID1B 在 ALL 中的功能。
采用实时 PCR 检测 ALL 患者 JARID1B mRNA 表达水平,选择健康志愿者外周血单个核细胞作为对照。用 MOLT-4 细胞和 BALL-1 细胞转染 JARID1B shRNA。用 Western blot 检测 JARID1B 蛋白表达及 H3K4me2 和 H3K4me3 水平。用 3-(4,5-二甲基-2-噻唑基)-2,5-二苯基-2-H-四唑溴盐(MTT)比色法检测细胞增殖。用流式细胞术检测细胞凋亡和细胞周期。用 Western blot 检测 Bcl-2、Bax、Procaspase 3 和细胞周期蛋白 P21 的表达。
ALL 患者原代骨髓细胞 JARID1B mRNA 表达明显高于健康志愿者(p<0.05)。JARID1B shRNA 转染后,组蛋白 H3K4me3 和 H3K4me2 水平上调。与对照组相比,JARID1B shRNA 显著抑制 MOLT-4 和 BALL-1 细胞增殖,诱导细胞凋亡,阻滞细胞周期于 G0/G1 期(p<0.05)。
JARID1B 在 ALL 中高表达。下调其表达通过组蛋白 H3K4 甲基化抑制白血病细胞增殖,促进细胞凋亡,阻滞细胞周期于 G0/G1 期。JARID1B 是 ALL 的癌基因。